Enliven Therapeutics (ELVN) Competitors $29.41 -0.14 (-0.47%) (As of 01:50 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ELVN vs. AVDL, NTLA, DCTH, EDIT, FULC, CORT, BHVN, BBIO, RARE, and OGNShould you be buying Enliven Therapeutics stock or one of its competitors? The main competitors of Enliven Therapeutics include Avadel Pharmaceuticals (AVDL), Intellia Therapeutics (NTLA), Delcath Systems (DCTH), Editas Medicine (EDIT), Fulcrum Therapeutics (FULC), Corcept Therapeutics (CORT), Biohaven (BHVN), BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), and Organon & Co. (OGN). These companies are all part of the "medical" sector. Enliven Therapeutics vs. Avadel Pharmaceuticals Intellia Therapeutics Delcath Systems Editas Medicine Fulcrum Therapeutics Corcept Therapeutics Biohaven BridgeBio Pharma Ultragenyx Pharmaceutical Organon & Co. Enliven Therapeutics (NASDAQ:ELVN) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, valuation and dividends. Does the MarketBeat Community prefer ELVN or AVDL? Avadel Pharmaceuticals received 332 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Enliven Therapeutics an outperform vote while only 65.89% of users gave Avadel Pharmaceuticals an outperform vote. CompanyUnderperformOutperformEnliven TherapeuticsOutperform Votes8100.00% Underperform VotesNo VotesAvadel PharmaceuticalsOutperform Votes34065.89% Underperform Votes17634.11% Is ELVN or AVDL more profitable? Enliven Therapeutics has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -111.64%. Enliven Therapeutics' return on equity of -29.31% beat Avadel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Enliven TherapeuticsN/A -29.31% -27.25% Avadel Pharmaceuticals -111.64%-122.64%-61.29% Do insiders & institutionals believe in ELVN or AVDL? 95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. 29.2% of Enliven Therapeutics shares are owned by insiders. Comparatively, 4.8% of Avadel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable valuation and earnings, ELVN or AVDL? Enliven Therapeutics has higher earnings, but lower revenue than Avadel Pharmaceuticals. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Avadel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnliven TherapeuticsN/AN/A-$71.58M-$1.93-15.24Avadel Pharmaceuticals$27.96M54.13-$160.28M-$1.17-13.44 Which has more risk & volatility, ELVN or AVDL? Enliven Therapeutics has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Do analysts rate ELVN or AVDL? Enliven Therapeutics currently has a consensus price target of $34.33, suggesting a potential upside of 16.74%. Avadel Pharmaceuticals has a consensus price target of $24.71, suggesting a potential upside of 57.22%. Given Avadel Pharmaceuticals' higher possible upside, analysts plainly believe Avadel Pharmaceuticals is more favorable than Enliven Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enliven Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Avadel Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer ELVN or AVDL? In the previous week, Avadel Pharmaceuticals had 9 more articles in the media than Enliven Therapeutics. MarketBeat recorded 10 mentions for Avadel Pharmaceuticals and 1 mentions for Enliven Therapeutics. Avadel Pharmaceuticals' average media sentiment score of 0.49 beat Enliven Therapeutics' score of -0.15 indicating that Avadel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avadel Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryEnliven Therapeutics and Avadel Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELVN vs. The Competition Export to ExcelMetricEnliven TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.39B$6.84B$5.31B$8.94BDividend YieldN/A7.97%5.09%4.03%P/E Ratio-15.248.63123.6916.61Price / SalesN/A408.091,369.1799.21Price / CashN/A46.4738.7933.99Price / Book4.935.564.915.35Net Income-$71.58M$153.40M$117.95M$223.73M7 Day Performance5.60%3.01%4.48%4.57%1 Month Performance7.14%19.29%10.36%7.41%1 Year Performance135.28%42.12%37.79%28.33% Enliven Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELVNEnliven Therapeutics1.225 of 5 stars$29.41-0.5%$34.33+16.7%+140.2%$1.39BN/A-15.2450Upcoming EarningsAVDLAvadel Pharmaceuticals2.7602 of 5 stars$15.05-2.7%N/A+42.5%$1.45B$27.96M-12.86154Upcoming EarningsNTLAIntellia Therapeutics4.441 of 5 stars$14.81+4.1%N/A-41.9%$1.50B$36.28M-2.70600DCTHDelcath Systems2.9585 of 5 stars$10.50-3.6%N/A+244.0%$291.80M$2.07M-4.1276Upcoming EarningsNews CoverageEDITEditas Medicine4.6933 of 5 stars$2.91+0.3%N/A-60.5%$240.02M$78.12M-1.23230Earnings ReportAnalyst DowngradeAnalyst RevisionNews CoverageFULCFulcrum Therapeutics3.7205 of 5 stars$3.21+1.6%N/A-4.5%$200.30M$2.81M-9.17100Positive NewsCORTCorcept Therapeutics4.7353 of 5 stars$47.62-2.8%N/A+109.3%$4.99B$482.38M37.79300Insider SellingAnalyst RevisionBHVNBiohaven3.0356 of 5 stars$50.88+2.3%N/A+85.7%$4.81B$462.51M-5.56239Upcoming EarningsPositive NewsBBIOBridgeBio Pharma4.6683 of 5 stars$25.48+8.8%N/A-8.1%$4.79B$9.30M-9.69400RAREUltragenyx Pharmaceutical4.7433 of 5 stars$50.99flatN/A+33.7%$4.70B$434.25M-6.981,276Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageOGNOrganon & Co.4.8878 of 5 stars$18.07-3.8%N/A+25.6%$4.65B$6.41B3.5910,000Earnings ReportDividend Announcement Related Companies and Tools Related Companies Avadel Pharmaceuticals Competitors Intellia Therapeutics Competitors Delcath Systems Competitors Editas Medicine Competitors Fulcrum Therapeutics Competitors Corcept Therapeutics Competitors Biohaven Competitors BridgeBio Pharma Competitors Ultragenyx Pharmaceutical Competitors Organon & Co. Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ELVN) was last updated on 11/7/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredHow high could Bitcoin go?Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELVN Stock Alerts